Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 14/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901971 | 0.95 | KDR (0.49) | KDRDYRK1ARETGAKACVR2A | |
| SCHEMBL12461270 | 0.88 | KDR (0.53) | KDRCYP3A4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL12461844 | 0.88 | DYRK1A (0.45) | KDRDYRK1ARETGAKACVR2A | |
| SCHEMBL12461830 | 0.87 | ERN1 (0.47) | RETGAKACVR2AERN1 | |
| SCHEMBL12461307 | 0.85 | ERN1 (0.48) | RETGAKACVR2AERN1 | |
| SCHEMBL1903502 | 0.85 | KDR (0.50) | KDRRETGAKACVR2A | |
| SCHEMBL12461662 | 0.84 | RET (0.39) | KDRDYRK1ARETACVR2A | |
| SCHEMBL12461799 | 0.82 | RET (0.48) | KDRRETGAK | |
| SCHEMBL12461272 | 0.82 | RET (0.49) | RETGAK | |
| SCHEMBL12461614 | 0.82 | RET (0.56) | RETACVR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | KDR 1534/4885DYRK1A 281/4885RET 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.